Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2504563 | 0.93 | — | — | |
| SCHEMBL1555745 | 0.93 | HTR2A (0.32) | HTR2A | |
| SCHEMBL2481710 | 0.88 | — | — | |
| SCHEMBL4159070 | 0.86 | — | — | |
| SCHEMBL337666 | 0.80 | — | — | |
| SCHEMBL3703784 | 0.78 | NEK2 (0.31) | — | |
| SCHEMBL942688 | 0.77 | — | — | |
| SCHEMBL206448 | 0.75 | — | — | |
| SCHEMBL1359784 | 0.73 | — | — | |
| SCHEMBL18693137 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024150146-A1 | ENGINEERED KETOREDUCTASE POLYPEPTIDES | NOVARTIS AG (CH) | 2024-07-18 | — | — | WO | disclosed |
| US-20240166643-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2024-05-23 | — | — | US | disclosed |
| WO-2024073133-A1 | PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS | AZKARRA THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-11932650-B2 | Potent agelastatin derivatives as modulators for cancer invasion and metastasis | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-03-19 | — | — | US | disclosed |
| US-11919839-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | VALO HEALTH, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| EP-3945091-B1 | NOVEL VDAC1 INHIBITORS | ABARCEO AB (SE) | 2024-01-03 | — | — | EP | disclosed |
| WO-2023238078-A1 | (S)-ENGINEERED OXYNITRILASE POLYPEPTIDES AND USES THEREOF | NOVARTIS AG (CH) | 2023-12-14 | — | — | WO | disclosed |
| EP-3571187-B1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH INC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230348464-A1 | NOVEL VDAC1 INHIBITORS | ABARCEO PHARMA AB (SE) | 2023-11-02 | — | — | US | disclosed |
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| EP-1853585-A1 | 3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID 5-AMINOPYRIDIN-2-YL ESTERS | Novo Nordisk A/S (DK) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007125103-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125105-A2 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007110364-A1 | BENZOTHIAZOLES HAVING HISTAMINE H3 RECEPTOR ACTIVITY | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007107550-A1 | ADAMANTANE DERIVATIVES FOR THE TREATMENT OF THE METABOLIC SYNDROME | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007101864-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007071766-A2 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | TRANSTECH PHARMA (US) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007003581-A1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007003604-A2 | HISTS1MINE H3 RECEPTOR ANTAGONISTS | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | WO | disclosed |
| WO-2006087309-A1 | 3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID 5-AMINOPYRIDIN-2-YL ESTERS | NOVO NORDISK A/S (DK) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166643-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | ABL1, TPMT, IDH2 | HTR2A 1266/4885 |
| US-11932650-B2 | Potent agelastatin derivatives as modulators for cancer invasion and metastasis | MMP2, MMP3, MMP10 | HTR2A 4633/4885 |
| US-20230348464-A1 | NOVEL VDAC1 INHIBITORS | VDAC1, HVCN1, VDAC2 | HTR2A 3300/4885 |
| US-11919839-B2 | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors | HDAC8, HDAC7, HDAC1 | HTR2A 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.